Prestige Biopharma Belgium SPRL
Prestige Biopharma Belgium reported total assets of 3,266 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Dec 2025).
The score of Prestige Biopharma Belgium shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -96 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Prestige Biopharma Belgium's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −350,950 € | ||||
| Equity | −889,292 € | ||||
| Cash | 1,130 € | ||||
| EBITDA | −335,472 € | ||||
| Total assets | 3,266 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 30 Dec 2025
- Year ended 30 Jun 2024filed on 19 Dec 2024
- Year ended 30 Jun 2023filed on 31 Dec 2023
- Year ended 30 Jun 2022filed on 06 Dec 2022
- Year ended 30 Jun 2021filed on 28 Dec 2021
Prestige Biopharma Belgium's financial analysis
- Solvency-27224.8%sector median: 55.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Prestige Biopharma Belgium
Prestige Biopharma Belgium's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0694.655.503
- VAT number
- No VAT activity declared to the CBE
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SPRL
- Incorporated
- 11 Apr 2018
- Registered office
- 3090 Overijse
- Latest accounts
- 2025 · filed on 30 Dec 2025
- Activity
- Other information service activities (NACE 63920)
Prestige Biopharma Belgium (SPRL) has been based in Overijse since 2018, active in: other information service activities. For 2025, it reports a net loss of 350,950 € and equity of −889,292 €; its revenue is not published.
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Prestige Biopharma Belgium
Companies in the same business, of comparable size and area, outside its group.
- A.L.V. Installation of industrial machinery and equipment Edegem · balance sheet 3,266 €
- Bouw & Electra Dorchain Gistel · balance sheet 3,267 €
- RL Projects Buying and selling of own real estate Diepenbeek · balance sheet 3,261 €
- Zilberman Rental and operating of own or leased real estate Schaerbeek · balance sheet 3,273 €
- Del Grosso Corporation Molenbeek-Saint-Jean · balance sheet 3,259 €
Frequently asked questions about Prestige Biopharma Belgium
What is the revenue of Prestige Biopharma Belgium?
Prestige Biopharma Belgium files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Prestige Biopharma Belgium?
According to the Crossroads Bank for Enterprises, no VAT-liable activity is declared for Prestige Biopharma Belgium. If it is VAT-registered, its VAT number is its company number prefixed with BE: BE0694655503. Its company number (CBE) is 0694.655.503.
Where is the registered office of Prestige Biopharma Belgium?
According to the CBE register, the registered office of Prestige Biopharma Belgium is in 3090 Overijse.
What is the equity of Prestige Biopharma Belgium?
At the close of the 2025 financial year, the equity of Prestige Biopharma Belgium amounts to -889,292 €, a solvency of -27224.8% of total assets.
Who manages Prestige Biopharma Belgium?
The register lists 1 active mandates at Prestige Biopharma Belgium. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Prestige Biopharma Belgium
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →